DX-8951f in Treating Patients With Biliary Cancer

Completed · Phase 2

Conditions studied: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have biliary cancer.

Key facts

Study ID

NCT00005938

Run by

Daiichi Sankyo

Starts

2000-03-01

Expected to finish

2005-04-01

Last updated by the study team

2012-05-16

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Colorado Cancer Center — Denver, Colorado, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Simmons Cancer Center - Dallas — Dallas, Texas, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• Cancer Therapy & Research Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.